This study is looking at how oral iron, specifically Ferrous Sulfate, affects children aged 1 to 21 years old who have chronic kidney disease (CKD) and mild anemia (low red blood cell count). You might be able to join if your child's kidneys aren't working as well as they should (estimated glomerular filtration rate or GFR less than 90) and they have mild anemia. The study will compare children who receive Ferrous Sulfate to those who don't, over a 3-month period. Researchers will measure changes in muscle strength and the amount of iron in the blood (transferrin saturation) to see if the treatment is helpful. The study plans to enroll 40 participants.

Study design

This is a pilot study that will randomly assign 40 participants to either receive oral iron (Ferrous Sulfate) or no iron therapy. The study will last for 3 months.

What's involved

Participants will receive oral iron (Ferrous Sulfate) daily for 3 months, or no iron therapy. Muscle strength, physical activity, and eating behavior will be measured at the beginning and end of the 3-month study period.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for 3 months, with measurements taken at the start and end of this period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.